✉ Email this page to a colleague
« Back to Dashboard
Momelotinib is an investigational drug.
There have been 16 clinical trials for Momelotinib. The most recent clinical trial was a Phase 3 trial, which was initiated on December 6th 2013.
The most common disease conditions in clinical trials are Thrombocythemia, Essential, Primary Myelofibrosis, and Polycythemia Vera. The leading clinical trial sponsors are Sierra Oncology, Inc., Gilead Sciences, and Covance.
There are two hundred and fifty-nine US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Momelotinib
|A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM)||Sierra Oncology, Inc.||Phase 3|
|Extended Access of Momelotinib in Adults With Myelofibrosis||Gilead Sciences||Phase 2|
|Extended Access of Momelotinib in Adults With Myelofibrosis||Sierra Oncology, Inc.||Phase 2|
Top disease conditions for Momelotinib
Top clinical trial sponsors for Momelotinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Momelotinib||⤷ Try a Trial||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||⤷ Try a Trial|
|Momelotinib||⤷ Try a Trial||Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor||Pharmacyclics LLC (Sunnyvale, CA)||⤷ Try a Trial|
|Momelotinib||⤷ Try a Trial||Bicyclic bromodomain inhibitors||Zenith Epigenetics Ltd. (Calgary, AB, CA)||⤷ Try a Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Momelotinib||Australia||AU2015244171||2034-04-11||⤷ Try a Trial|
|Momelotinib||Australia||AU2015244179||2034-04-11||⤷ Try a Trial|
|Momelotinib||Canada||CA2945128||2034-04-11||⤷ Try a Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|